SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-006824
Filing Date
2019-08-01
Accepted
2019-08-01 16:23:44
Documents
64
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20190630x10q.htm 10-Q 2016616
2 EX-31.1 crvs-20190630ex31172e31d.htm EX-31.1 13520
3 EX-31.2 crvs-20190630ex312f0cf00.htm EX-31.2 13463
4 EX-32.1 crvs-20190630ex321f75549.htm EX-32.1 13625
  Complete submission text file 0001558370-19-006824.txt   6313388

Data Files

Seq Description Document Type Size
5 EX-101.INS crvs-20190630.xml EX-101.INS 1321085
6 EX-101.SCH crvs-20190630.xsd EX-101.SCH 38202
7 EX-101.CAL crvs-20190630_cal.xml EX-101.CAL 53358
8 EX-101.DEF crvs-20190630_def.xml EX-101.DEF 104896
9 EX-101.LAB crvs-20190630_lab.xml EX-101.LAB 367886
10 EX-101.PRE crvs-20190630_pre.xml EX-101.PRE 258305
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 19993032
SIC: 2834 Pharmaceutical Preparations